Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

National Mental Health Strategy 2024-2030

Executive Summary
 
We can all play a role in promoting and safeguarding mental health for all population groups and in supporting individuals going through difficult times. This strategy serves as a seven-year roadmap aimed at guiding the Ministry of Public Health and all relevant stakeholders while mobilizing efforts to improve mental health in Lebanon. In Lebanon, in particular, improving mental health also requires addressing the social, economic, and political factors that negatively impact mental well-being and hinder the recovery process.
 
The strategy was developed using a comprehensive approach to address key issues. First, an assessment of the mental health situation in the country was conducted, including the burden of diseases, needs, and an evaluation of the existing system’s ability to meet these needs. Previous efforts were also reviewed to identify areas that need to be maintained and those requiring improvement. Furthermore, consultations were held with experts and local stakeholders, including individuals with lived experiences, to help set strategic priorities. The strategy was also guided by international frameworks, including World Health Organization (WHO) guidelines and other evidence-based recommendations. Special care was taken to select approaches that are appropriate and adaptable to the local context. Finally, the strategy was published and made available to the public for feedback and revisions.
 
The strategy addresses all fundamental aspects of the mental health system to enhance overall mental well-being and prevent mental disorders, with a focus on the following key areas:
  • Raising awareness about mental health, reducing misconceptions, and implementing evidence-based interventions to prevent mental health issues. This includes emphasizing the importance of addressing political, social, and economic factors that influence mental health.
  • Empowering individuals by providing them with the resources, knowledge, and skills necessary to protect their mental well-being and ensuring access to available services when needed.
  • Ensuring that individuals with mental health disorders can access high-quality care whenever they need it, regardless of their place of residence.
  • Supporting healthcare providers and all professionals in the field by building their capacity based on evidence-based practices and helping them safeguard their own mental health.
  • Preventing and reducing harmful practices that violate human rights and quality standards in the provision of mental health services.
  • Enhancing data availability and conducting valuable research to guide and support efforts to improve mental health across the country.
  • Establishing legal frameworks, policies, and appropriate funding mechanisms to strengthen the mental health system.
  • Integrating the views, perspectives, and preferences of individuals with lived experiences in the design, development, and implementation of services, policies, and practices.
Specific actions have been planned for each of these key areas to ensure the necessary improvements in the country.
 

 
National Mental Health Strategy 2024-2030 (Please click on this link to download the document)
 
Theory of Change Map (Please click on this link to download the document)

Executive Summary (English, French, Arabic) 
 
    ...
    151
    ...
ATC Name B/G Ingredients Dosage Form Price
L01BC05 GEMTABINE 1000 G Gemcitabine HCl - 1,000mg 1,000mg Injectable lyophilised powder for solution 4,882,628 L.L
N02BE01 BBDOL-OR G Paracetamol - 120mg/5ml 120mg/5ml Syrup 188,138 L.L
N05AE05 LAROZA G Lurasidone - 80mg 80mg Tablet, film coated 5,548,726 L.L
R03BA01 CORTIS G Beclometasone dipropionate - 250mcg/actuation 250mcg/actuation Inhalation solution 674,609 L.L
S01AE02 NAFLOX G Norfloxacin - 3mg/ml 3mg/ml Drops 370,901 L.L
A03FA01 METOCLOPRAMIDE S.A.L.F. G Metoclopramide HCl - 10mg/2ml 10mg/2ml Injectable solution 255,330 L.L
A10BB12 DIAMERIL G Glimepiride - 2mg 2mg Tablet 199,657 L.L
B05BB01 LR G Sodium lactate - 0.3g/100ml, Calcium chloride, 2H2O - 0.02g/100ml, Potassium chloride - 0.03g/100ml, Sodium chloride - 0.598g/100ml Injectable solution 234,862 L.L
B05XA31 NUTRYELT G Zinc (gluconate) - 10000mcg/10ml, Copper (gluconate) - 300mcg/10ml, Manganese (gluconate) - 55mcg/10ml, Sodium fluoride - 950mcg/10ml, Iodine potassium iodide - 130mcg/10ml, Selenium (sodium salt) - 70mcg/10ml, Molybdenum (Sodium molybdate) - 20mcg/10ml, Chrome (chlorure) - 10mcg/10ml, Ferrous (gluconate) - 1000mcg/10ml Injectable concentrate for solution 3,483,240 L.L
C08CA01 AMLINE G Amlodipine - 5mg 5mg Tablet, scored 358,358 L.L
D02AF METHYL SALICYLATE COMPOUND UNGUENTUM G Methylsalicylate - 4.5g/30g, Menthol - 1.8g/30g Ointment 165,101 L.L
G02CB03 PROCTIN G Cabergoline - 0.5mg 0.5mg Tablet 1,300,328 L.L
H02AB06 PREDO G Prednisolone sodium phosphate - 15mg/5ml 15mg/5ml Syrup 1,018,633 L.L
J01DD08 MAGNACEF 400 G Cefixime - 400mg 400mg Capsule 1,307,559 L.L
J02AC01 FUNZOL 150 G Fluconazole - 150mg 150mg Capsule 170,668 L.L
L01BC05 HAXANIT G Gemcitabine (HCl) - 1g 1g Injectable lyophilised powder 6,829,408 L.L
M02AA07 PIROXICALM G Piroxicam - 0.5% 0.5% Gel 207,336 L.L
N02BE01 PAINOL G Paracetamol - 120mg/5ml 120mg/5ml Elixir 85,750 L.L
N05AE05 LURABIL G Lurasidone - 80mg 80mg Tablet, film coated 2,535,831 L.L
N06AX26 LYTIOX G Vortioxetine - 10mg 10mg Tablet, film coated 2,064,142 L.L
R03BA02 AERONIDE G Budesonide - 200mcg 200mcg Capsule, inhalation 1,150,329 L.L
A03FA01 METORAM G Metoclopramide HCl - 10mg/2ml 10mg/2ml Injectable solution 421,071 L.L
A10BB12 GLIM G Glimepiride - 2mg 2mg Tablet 401,809 L.L
B05BB01 SERUFLEX LACTATED RINGER'S INJECTION, USP G Sodium lactate - 3.1g/l, Calcium chloride, 2H2O - 0.2g/l, Potassium chloride - 0.3g/l, Sodium chloride - 6g/l Injectable solution 232,134 L.L
B05XA31 ADDAVEN G Chromic chloride 6H2O - 53mcg/10ml, Copper chloride dihydrate - 1.02mg/10ml, Ferric Chloride hexahydrate - 5.40mg/10ml, Manganese chloride 4H2O - 198mcg/10ml, Potassium iodide - 166mcg/10ml, Sodium fluoride - 2.10mg/10ml Injectable concentrate for solution 4,065,124 L.L
C08CA01 AMLO TAD G Amlodipine besylate - 5mg 5mg Tablet 744,489 L.L
C09DB02 OLMENOR COMBI G Olmesartan medoxomil - 20mg, Amlodipine - 5mg Tablet, film coated 679,984 L.L
D02AF POMMADE ACIDE SALICYLIQUE G Salicylic acid - 10% 10% Ointment 284,127 L.L
G02CB03 PROCTINMED G Cabergoline - 0.5mg 0.5mg Tablet 473,545 L.L
H02AB06 PREDOXONE G Prednisolone sodium phosphate - 15mg/5ml 15mg/5ml Solution 417,231 L.L
    ...
    151
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025